Hypophosphataemia: An easy strategy for diagnosis and treatment in HIV patients

Antiviral Therapy

Volumn 14, Issue 4, 2009, Pages 481-488

  Bagnis, Corinne Isnard ^a   Karie, Svetlana ^a   Deray, Gilbert ^a   Essig, Marie ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CIDOFOVIR; COLECALCIFEROL; CREATININE; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

COST EFFECTIVENESS ANALYSIS; CREATININE URINE LEVEL; DIET SUPPLEMENTATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FANCONI RENOTUBULAR SYNDROME; GENE OVEREXPRESSION; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; KIDNEY TUBULE ABSORPTION; METABOLIC DISORDER; PATIENT MONITORING; PHOSPHATE URINE LEVEL; PREVALENCE; PRIORITY JOURNAL; REVIEW; VITAMIN D DEFICIENCY; BIOLOGICAL MODEL; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; HYPOPHOSPHATEMIA; MODELS, BIOLOGICAL; PREVALENCE; VITAMIN D DEFICIENCY;

EID: 68549104159     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Gaasbeek A, Meinders AE. Hypophosphatemia: an update on its etiology and treatment. Am J Med 2005; 118:1094-1101.
2. Badiou S, De Boever CM, Terrier N, Baillat V, Cristol JP, Reynes J. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-Positive adults? J Infect 2006; 52:335-138.
3. Bichacz K, Brooks JT, Tong T, et al. Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HFV-infected out-patients receiving highly active antiretroviral theraphy. HIV Med 2006; 7:451-456.
4. Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. Lancet 1998; 352:391-396.
5. Danisi G, Straub RW. Unidirectional influx of phosphate across the mucosal membraneof rabbit small intestine. Pflugers Arch 1980; 385:117-122.
6. Juan D, Liptak P, Gray TK. Absorption of inorganic phosphate in the human jejunum and its inhibition by salmon calcitonin. J Clin Endocrinol Metab 1976; 43:517-522.
7. Walling MW. Intestinal inorganic phosphate transport. Adv Exp Med Biol 1978; 103:131-147.
8. Betro MG, Pain RW. Hypophosphataemia and hyperphosphataemia in a hospital population. BMJ 1972; 1: 273-276.
9. Larsson L, Rebel K, Sorbo B. Severe hyporhosphatemia - a hospital survey. Acta Med Scand 1983; 214:221-223.
10. King AL, Sica DA, Miller G, Pierpaoli S. Severe hypophosphaterma in a general hospital population. South Med J 1987; 80:831-835.
11. Daily WH, Tonnesen AS, Allen SJ. Hypophosphatemia - incidence, etiology, and prevention in the trauma patient. Crit Care Med 1990; 18:1210-1214.
12. Marik PE, Bedigian MK. Refeeding hypophosghatemia in critically ill patients in an intensive care unit. prospective study. Arch Surg 1996; 131:1043-1047.
13. Zazzo JF, Troche G, Ruel P, Maintenant J. High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus thera y on myocardial function. Intensive Care Med 1995; 21:826-831.
14. Barak V, Schwartz A, Kalickman I, Nisman B, Gutman G, Shoenfeld Y. Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines. Am J Med 1998; 104:40-47.
15. Ryback RS, Eckardt MJ, Pautler CP. Clinical relationships between serum phosphorus and other blood chemistry values in alcoholics. Arch Intern Med 1980; 140:673-677.
16. Fiaccadori E, Coffrini E, Ronda N, et al. Hypophosphatemia in course of chronic obstructive pulmonary disease. Prevalence, mechanisms, and relationships with skeletal muscle phosphorus content. Chest 1990; 97:857-868.
17. Cross HS, Debiec H, Peterlik M. Mechanism and regulation of intestinal pbosphate absorption. Miner Electrolyte Metab 1990; 16:115-124.
18. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. FHV-protcase -inhibitors impair vitamin D bioaotivation to 1,25-dihydroxyvitamin D. AIDS 2003; 17:513-520.
19. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis 2006; 42:108-114.
20. Essig M, Duval X, Kaied FA, et al. Is phosphatemia the best tool to monitor renal tenofovir toxicity? J Acquir Immune Defic Syndr 2007; 46:256-258.
21. Polis MA, Spooner KM, Baird BF, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 1995; 39:882-886.
22. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis 2003; 41:292-309.
23. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res 2002; 54:37-45.
24. Vashistha H, Husain M, Kumar D, Yadav A, Arora S, Singhal PC. HIV-1 expression induces tubular cell G2/M arrest and apoptosis. Ren Fail 2008; 30:655-664.
25. Conaldi PG, Biancone L, Bottelli A, et al. HIV-1 kills renal tubular epithelial cells in vitro.by triggering an apoptotic pathway involving casyase activation and Fas upregulation. J Clin Invest 1998; 102:2041-2049.
26. Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet 1975; 306:309-310.
27. Amanzadeh J, Redly RF, Jr. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol 2006; 2:136-148.
28. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559-1585.
29. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281.